Claims for Patent: 8,043,250

Summary for Patent: 8,043,250

Title:	High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances
Abstract:	A method of usign a high-aspect ratio microdevice for treating, preventing or ameliorating a medical condition is provided.
Inventor(s):	Xu; Bai (Slingerlands, NY)
Assignee:	Nanomed Devices, Inc. (Slingerlands, NY)
Application Number:	11/510,078
Patent Claims:	1. A method of treating, preventing, or ameliorating a medical condition of a mammal, comprising: treating a topical site of a mammal using a device, immediately removing the device from the topical site after the device has perforated the skin, and applying an effective amount of an agent to the topical site to allow the agent to penetrate into the body of the mammal, wherein the device comprises an array of microstructures, and wherein the microstructure has an aspect ratio of about 10:1 or higher. 2. The method of claim 1, wherein the microstructure comprises microneedles, microknives or microblades, wherein the treating comprises pushing a plurality of microneedles, microblades, or microknives of a microstructure through the outer layer of skin on a preselected site of the skin, and wherein the applying comprises applying a skin patch containing the agent over the topical site after the device has been removed from the topical site. 3. The method of claim 1, wherein the agent is a therapeutic agent selected from the group consisting of antibiotics, hormones, steroids, anti-inflammatory drugs, protein drugs, DNA drugs, recombinant Erythropoietin (rhEPO), Taxol.RTM., Interferon-alpha-1b, Interferon beta, Interferon gamma, Emla.RTM., Fluorouracil, Lidocaine, Salicylic acid, Pureriran, eflornithine hydrochloride, spironolactone, flutamide, insulin, nanoparticle drugs, Epidural, recombinant human parathyroid hormone, growth hormone, thyroid, cortisol, estrogen, progesterone, testosterone and a combination thereof. 4. The method of claim 1, wherein the active agent is a natural or synthetic vaccine selected from the group consisting of vaccines, protein vaccines, peptide vaccines, gene vaccines and DNA vaccines, and wherein the vaccine is against influenza (flu), diphtheria, tetanus, pertussis (DTaP), measles, mumps, rubella (MMR), hepatitis B, polio, haemophilus influenzae type b, chickenpox, tuberculosis, anthrax, yellow fever, rabies, AIDS, cancers, meningococcus, SARS and cholera. 5. The method of claim 1, wherein the agent is a pain relieving agent. 6. The method of claim 5, wherein the medical condition is chronic back pain. 7. The method of claim 5, wherein the medical condition is a cancer. 8. A method of treating, preventing, or ameliorating a medical condition of a mammal, comprising: treating a topical site of a mammal using a device, immediately removing the device from the topical site after the device has perforated the skin, and applying an effective amount of an agent to the topical site to allow the agent to penetrate into the body of the mammal, wherein the device comprises an array of microstructures having an aspect ratio of about 10:1 or higher, wherein the microstructure is a microneedle, microblade, microknife, or a combination thereof, wherein the microneedle comprises a tip in nanoscale dimension and a body in microscale dimension, and wherein the microblade or microknife comprises an edge in nanoscale dimension and a body in microscale dimension. 9. The method of claim 8, wherein the treating comprises pushing a plurality of microneedles, microblades, or microknives of a microstructure through the outer layer of skin on a preselected site of the skin, and wherein the applying comprises applying a skin patch containing the agent over the topical site after the device has been removed from the topical site. 10. The method of claim 8, wherein the agent is a therapeutic agent selected from the group consisting of antibiotics, hormones, steroids, anti-inflammatory drugs, protein drugs, DNA drugs, recombinant Erythropoietin (rhEPO), Taxol.RTM., Interferon-alpha-1b, Interferon beta, Interferon gamma, Emla.RTM., Fluorouracil, Lidocaine, Salicylic acid, Pureriran, eflornithine hydrochloride, spironolactone, flutamide, insulin, nanoparticle drugs, Epidural, recombinant human parathyroid hormone, growth hormone, thyroid, cortisol, estrogen, progesterone, testosterone and a combination thereof. 11. The method of claim 8, wherein the active agent is a natural or synthetic vaccine selected from the group consisting of vaccines, protein vaccines, peptide vaccines, gene vaccines and DNA vaccines, and wherein the vaccine is against influenza (flu), diphtheria, tetanus, pertussis (DTaP), measles, mumps, rubella (MMR), hepatitis B, polio, haemophilus influenzae type b, chickenpox, tuberculosis, anthrax, yellow fever, rabies, AIDS, cancers, meningococcus, SARS and cholera. 12. The method of claim 8, wherein the agent is a pain relieving agent. 13. The method of claim 12, wherein the medical condition is chronic back pain. 14. The method of claim 12, wherein the medical condition is a cancer.

Details for Patent 8,043,250

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2025-05-18